A ₹650 crore procurement scam under investigation in Delhi has once again placed India’s public healthcare procurement system under intense scrutiny. The case, which involves alleged irregularities in the purchase of medicines, medical equipment, and healthcare consumables for government hospitals and Mohalla Clinics, is the latest in a series of scandals that have surfaced across the country over the past two decades.
From the ₹10,000 crore National Rural Health Mission (NRHM) scam in Uttar Pradesh to the ₹550 crore Chhattisgarh medical procurement fraud and recent controversies in Maharashtra and Puducherry, investigators have repeatedly uncovered a familiar pattern: inflated pricing, manipulated tenders, collusion between officials and vendors, poor quality control, and weak oversight mechanisms.
As Delhi’s Anti-Corruption Branch (ACB) expands its probe, experts say the case highlights systemic flaws that continue to put public funds and patient safety at risk.
The Delhi case centers on the Central Procurement Agency (CPA), the body responsible for centralized procurement of medicines, medical devices, diagnostic equipment, and consumables for government healthcare facilities across the national capital.
Authorities allege that officials within the CPA manipulated procurement processes by approving inflated purchases, favoring select vendors, and authorizing payments significantly higher than prevailing market rates. The investigation began after a vigilance complaint prompted scrutiny from both the Lieutenant Governor (LG) and the Chief Minister (CM), who subsequently directed a formal inquiry.
The ACB registered an FIR and has since issued notices to approximately 10 doctors and 45 officials associated with the CPA and various government hospitals. Investigators are examining procurement records, vendor selection processes, inventory management practices, and financial approvals connected to contracts worth an estimated ₹650 crore.
Vendors who brought the allegations forward specifically named the CPA’s Chief Medical Officer in connection with procurement transactions reportedly exceeding ₹350 crore. Amid the growing controversy, the Lieutenant Governor removed the Director of Health Services (DHS) from office, while dozens of doctors were transferred from their existing postings pending further investigation.
Officials have emphasized that the ₹650 crore procurement case is separate from the earlier controversy involving allegedly substandard medicines. In that matter, an internal Directorate General of Health Services (DGHS) committee concluded that certain medicine samples were substandard but did not meet the legal definition of “spurious” under the Drugs and Cosmetics Act. The current FIR focuses on financial irregularities, including overbilling, excessive procurement, and violations of procurement procedures.
The controversy has also exposed vulnerabilities in the broader supply chain. Separate investigations by Delhi Police and the Crime Branch recently uncovered rackets allegedly diverting government-supplied free medicines into private markets, demonstrating how weaknesses can extend beyond purchasing and into storage and distribution.
One of the most detailed procurement fraud investigations in recent years emerged in Chhattisgarh.
In April 2025, the Anti-Corruption Bureau (ACB) and Economic Offences Wing (EOW) filed an 18,000-page chargesheet in connection with a ₹550 crore medical procurement scam. Among the six accused were Shashank Chopda, director of Mokshit Corporation, along with serving and former officials of the Chhattisgarh Medical Services Corporation Limited (CGMSCL).
Investigators alleged that multiple private firms colluded to manipulate competitive bidding processes. Companies reportedly submitted fabricated eligibility documents and coordinated financial bids to ensure that Mokshit Corporation consistently emerged as the lowest bidder, despite quoting prices far above market rates.
The pricing disparities uncovered by investigators were staggering.
An EDTA blood collection tube that was available to other institutions for approximately ₹8.50 per unit was allegedly supplied to CGMSCL at ₹2,352 per piece. Similarly, a Complete Blood Count (CBC) machine with a market price of around ₹5 lakh was reportedly invoiced to the state corporation for ₹17 lakh.
Investigators concluded that this systematic overpricing, repeated across thousands of procurement items, generated losses estimated at ₹550 crore for the state exchequer.
The National Rural Health Mission (NRHM) scam in Uttar Pradesh remains one of the largest healthcare corruption cases in Indian history.
Between 2005 and 2011, investigators alleged that politicians, bureaucrats, contractors, and healthcare officials siphoned approximately ₹10,000 crore from funds allocated to strengthen healthcare delivery in rural areas.
The Central Bureau of Investigation (CBI) found evidence that Chief Medical Officers (CMOs), government officials, contractors, and medicine suppliers colluded to manipulate procurement and infrastructure projects. Fake tenders were allegedly floated, procurement norms ignored, and contracts awarded without competitive bidding.
Investigators found that projects involving the upgradation of 89 district hospitals were among those affected. Medicine suppliers from Moradabad and other regions were named in multiple CBI chargesheets.
More than 70 FIRs were eventually registered as the investigation expanded.
The scandal drew national attention not only because of its scale but also because of a series of suspicious deaths linked to the case. At least five individuals connected to the scandal, including witnesses and a key accused, died under mysterious circumstances, prompting allegations that efforts were made to suppress evidence and obstruct investigations.
More than a decade later, several prosecutions remain ongoing, making the NRHM case a lasting example of how deeply procurement corruption can become embedded within a state healthcare system.
In 2025 and 2026, Maharashtra faced a procurement controversy that directly affected public health programmes targeting anaemia among children and pregnant women.
Testing conducted by the Food and Drug Administration (FDA) found that iron syrup supplied under government health schemes failed safety standards and was considered unsafe for human consumption. Thousands of bottles stored at a Raigad Zilla Parishad warehouse reportedly failed quality assessments.
Following the findings, Chief Minister Devendra Fadnavis ordered the transfer of Mahesh Awhad, Chief Executive Officer of the Maharashtra Medical Goods Procurement Authority (MMGPA).
Authorities initially blacklisted the supplier responsible for the product for two years under procurement regulations. However, the decision was reportedly reversed within a month, triggering concerns about transparency and administrative interference.
The controversy deepened further when reports indicated that the same company could participate in a forthcoming ₹700 crore pharmaceutical procurement tender. Under the proposed tender, the supplier could potentially secure contracts worth ₹80 crore to ₹100 crore.
The Maharashtra episode demonstrated how procurement failures can pose direct risks to patients while raising concerns about whether accountability mechanisms remain effective once irregularities are identified.
Amid growing scrutiny of the alleged ₹650 crore procurement scam, Dr. Munish Kumar Raizada, Editor-in-Chief of NewsGram and MedBound Times, publicly questioned who should be held accountable for the alleged irregularities.
In a social media post, Dr. Raizada argued that if funds intended for patient care were diverted through corrupt procurement practices, the matter would represent not only a financial loss but also a breach of public trust in the healthcare system.
He highlighted allegations that certain medicines and medical equipment may have been purchased at prices significantly higher than market rates and referred to reports regarding missing procurement-related documents. Citing the filing of an FIR by the Anti-Corruption Branch (ACB), he suggested that the investigation reflects the seriousness of the allegations.
Dr. Raizada posed several questions that have become central to the public debate surrounding the case:
Who is responsible for the alleged ₹650 crore scam?
Under whose watch did the alleged irregularities continue within government hospital procurement systems?
Who will ultimately be held accountable if wrongdoing is established?
It is important to note that the allegations remain under investigation, and no court has yet determined criminal liability in the case.
Although much smaller in financial terms, the procurement scandal uncovered in Puducherry raised serious concerns about patient safety.
The Department of Vigilance and Anti-Corruption (DVAC) arrested six individuals, including three former senior Health Department officials, in connection with the procurement of substandard and expired medicines for government hospitals and educational institutions.
Investigators focused on iron sucrose injections procured from Sri Sai Ram Agency and Padmajothi Agency and distributed to Primary Health Centres across the Union Territory.
Laboratory testing reportedly confirmed that several batches were either substandard or had exceeded their expiry dates before distribution.
Authorities estimated losses exceeding ₹2 crore and registered cases under Sections 409 and 420 of the Indian Penal Code (IPC), along with Section 13(1)(a) of the Prevention of Corruption Act.
The case highlighted how procurement irregularities can directly affect patient treatment, even when the financial value of the fraud appears relatively modest compared to larger scandals elsewhere.
Medical technology procurement differs significantly from purchasing routine hospital supplies.
Hospitals buy thousands of products ranging from syringes and surgical consumables to advanced imaging systems, cardiac devices, intensive care equipment, and laboratory analyzers. These products vary widely in technology, quality standards, maintenance requirements, and pricing structures.
This complexity creates opportunities for:
Price inflation
Vendor favoritism
Technical specification manipulation
Excess procurement
Poor inventory management
Underutilization of equipment
Many state medical services corporations and procurement agencies continue to operate without sufficient independent oversight. In several instances, the same officials responsible for evaluating tenders also exercise significant control over procurement approvals, creating opportunities for conflicts of interest.